Question: I have KRAS+ lung cancer. Are there any clinical trials available for me?  

Answer: Yes! No matter what kind of lung cancer you are diagnosed with, there is likely a trial appropriate for you.  

GO2 for Lung Cancer has our own KRAS study — launched with our medical research consortium, the Addario Lung Cancer Medical Institute (ALCMI), and in collaboration with Dr. Mark Awad, Dana Farber Cancer Institute, and Foundation Medicine. This study, called SPARK, is for anyone with lung cancer who: 

  • Lives in the United States 
  • Has been treated with a KRAS inhibitor like Lumakras (sotorasib) or Krazati (adagrasib) and  
  • Has had a recurrence on one of those drugs 

Participants in SPARK will have their blood drawn at home or through a local provider. They will not have to travel, have a biopsy, or change doctors to participate. Their blood will be sent for a liquid biopsy analysis at Foundation Medicine and the results will be studied by Dr. Awad and his team to understand the patterns of how lung cancer can progress while on KRAS inhibitor drugs. A copy of the report will also be given to study participants and their oncologists in case it is helpful for making treatment decisions.  

We hope the SPARK study will help us to understand, anticipate, and overcome KRAS drug resistance and potentially help researchers discover new lines of treatment for people with KRAS+ lung cancer.   

There are also other clinical trials for people with KRAS+ lung cancer. GO2’s treatment and clinical trial navigation service, LungMATCH, can help you determine which one(s) might be best for you. Connect with the LungMATCH navigators by emailing support@go2.org or calling 1-800-298-2436 to learn more about your treatment and trial options.  

You can find more information about participating in SPARK here.